ReviewCurrent opinion in structural biology2022
Glycosylation as a key parameter in the design of nucleic acid vaccines.
Review in Current opinion in structural biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- A circular RNA vaccine induces durable and cross-protective immunity against Neisseria meningitidis serogroup B in mice.PLoS pathogens · 2026Article
- Molecular mechanisms of immune evasion by host protein glycosylation of a bacterial immunogen used in nucleic acid vaccines.The Journal of biological chemistry · 2026Article
- Applying principles of vaccine development to oncomicrobial vaccines.Blood advances · 2025Review
- mRNA vaccine expressing enterovirus D68 virus-like particles induces potent neutralizing antibodies and protects against infection.Molecular therapy. Nucleic acids · 2025Article
- Design and Analysis of Novel HEV Vaccine Variants and Evaluation of Two Selected Candidates in a Porcine Infection Model.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
- Challenges and opportunities in mRNA vaccine development against bacteria.Nature microbiology · 2025Review
- Engineering and structures of Crimean-Congo hemorrhagic fever virus glycoprotein complexes.Cell · 2025Article
- Future Sequon Finder - A novel approach for predicting future N-linked glycosylation sequon locations on viral surface proteins.PloS one · 2025Article
- Article
- Review
- Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization.PLoS pathogens · 2023Article
- Progress and prospects on vaccine development against monkeypox infection.Microbial pathogenesis · 2023Review
- Nucleotide sugar transporter SLC35A2 is involved in promoting hepatocellular carcinoma metastasis by regulating cellular glycosylation.Cellular oncology (Dordrecht, Netherlands) · 2023Article
- A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium.Science advances · 2023Article
- Impact of mutations on the plant-based production of recombinant SARS-CoV-2 RBDs.Frontiers in plant science · 2023Article
- Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview.Virology journal · 2022Review
- Characterization and immunogenicity of SARS-CoV-2 spike proteins with varied glycosylation.Vaccine · 2022Article
- Analysis of Viral Spike Protein N-Glycosylation Using Ultraviolet Photodissociation Mass Spectrometry.Analytical chemistry · 2022Article
- Transient Expression of Glycosylated SARS-CoV-2 Antigens inPlants (Basel, Switzerland) · 2022Review
- In silico design of refined ferritin-SARS-CoV-2 glyco-RBD nanoparticle vaccine.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Vaccine-induced immunity is expected to target the native antigens expressed by the pathogens. Therefore, it is highly important to generate vaccine antigens that are immunologically indistinguishable from the native antigens. Nucleic acid vaccines, comprised of DNA, mRNA, or recombinant viral vector vaccines, introduce the genetic material encoding the antigenic protein for the host to express. Because these proteins will undergo host posttranslational modifications, host glycosylation can potentially alter the structure and immunological efficacy of the antigen. In this review, we discuss the potential impact of host protein glycosylation on the immune responses generated by nucleic acid vaccines against bacterial and viral pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.